Share on StockTwits

Equities researchers at Summer Street began coverage on shares of Medical Transcription Billing Corp (NASDAQ:MTBC) in a research report issued on Wednesday. The firm set a “buy” rating and a $9.00 price target on the stock. Summer Street’s target price would indicate a potential upside of 159.37% from the stock’s previous close.

Separately, analysts at Chardan Capital initiated coverage on shares of Medical Transcription Billing Corp in a research note on Wednesday, August 13th. They set a “buy” rating and a $11.00 price target on the stock.

Shares of Medical Transcription Billing Corp (NASDAQ:MTBC) opened at 3.39 on Wednesday. Medical Transcription Billing Corp has a 52 week low of $3.00 and a 52 week high of $5.00. The stock’s 50-day moving average is $3.50 and its 200-day moving average is $3.50. The company’s market cap is $17.3 million.

Medical Transcription Billing Corp (NASDAQ:MTBC) last released its earnings data on Wednesday, August 27th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.05) by $0.04. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $2.60 million. On average, analysts predict that Medical Transcription Billing Corp will post $-0.44 earnings per share for the current fiscal year.

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.